Gene Signal International SA.

Gene Signal is developing a robust pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions based on its innovative angiogenesis modulating technology. Gene Signal’s diverse pipeline also includes four molecules at the discovery stage addressing indications in the field of vascular disease and oncology.

Through world leading expertise in discovering genes involved in the regulation of angiogenesis, Gene Signal has built a significant intellectual property portfolio that has relevance in multiple disease areas. Gene Signal plans to license out its therapeutic portfolio of candidate drugs for co-development and commercialisation. The company was founded in 2000 and has assembled an outstanding leadership team that includes scientific, medical, regulatory and business professionals with successful track records in developing and commercialising state of the art drugs. Gene Signal’s headquarters are in Lausanne, Switzerland, with its research programs based in France and product development in Canada.